<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369688">
  <stage>Registered</stage>
  <submitdate>25/11/2015</submitdate>
  <approvaldate>30/11/2015</approvaldate>
  <actrnumber>ACTRN12615001302549</actrnumber>
  <trial_identification>
    <studytitle>The influence of genetic variants on inosine-induced hyperuricaemia</studytitle>
    <scientifictitle>The influence of genetic variants on inosine-induced hyperuricaemia in healthy adult volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gout</healthcondition>
    <healthcondition>Hyperuricaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral inosine 1.5g will be administered under direct observation on a single occasion to all participants. Participants will then be observed for three hours.</interventions>
    <comparator>Comparison between individuals possessing at least one protective allele at the SLC2A9 SNP rs11942223 and those without the protective allele
Comparison between individuals possessing at least one ABCG2 141K variant and those without the 141K variant.
These alleles are determined by testing a blood sample. </comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in serum urate concentration following a inosine challenge (blood test)</outcome>
      <timepoint>15 minutes, 30 minutes, 60 minutes, 120 minutes, and 180 minutes after ingestion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fractional excretion of urate to 3 hours following a inosine challenge (blood and urine test)</outcome>
      <timepoint>Blood and urine tests will be taken at the following time points: 30 minutes, 60 minutes, 120 minutes, and 180 minutes after ingestion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a.	Able to provide written informed consent
b.	eGFR&gt;60 mL/min/1.73 m2
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>a.	History of gout
b.	History of kidney stones
c.	History of diabetes mellitus
d.	Diuretic use
e.	Urine pH less than or equal to 5.0 (risk factor for uric acid urolithiasis)
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/02/2016</anticipatedstartdate>
    <actualstartdate>3/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/08/2016</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress>85 Park Rd
Grafton Auckland 1023</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council</fundingname>
      <fundingaddress>Level 3 - ProCARE Building, Grafton Mews, at 110 Stanley Street, Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress>NA</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This intervention study is designed to to examine the influence of genetic variation on inosine-induced hyperuricaemia.  The primary endpoint is change in serum urate over 180 minutes after inosine ingestion.  Key secondary and exploratory endpoints are change in fractional excretion of urate.  The key genes of interest are SLC2A9 (GLUT9) and ABCG2. However, other genes associated with purine synthesis and urate transport may also be examined in later exploratory analyses.  </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health and Disability Ethics Committee</ethicname>
      <ethicaddress>C/- MEDSAFE, Level 6, Deloitte House
10 Brandon Street
PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>21/12/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>4/12/2015</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Room 502-201D Bone and Joint Research Group Department of Medicine Faculty of Medical and Health Sciences University of Auckland 85 Park Rd, Grafton, Auckland 1023</address>
      <phone> +64 (0) 9 3737999 x82568 </phone>
      <fax> +64 (0) 9 3737677</fax>
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anne Horne</name>
      <address>Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023</address>
      <phone>+64 (0) 9 3737999 x89787</phone>
      <fax> +64 (0) 9 3737677</fax>
      <email>a.horne@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Nicola Dalbeth</name>
      <address>Bone and Joint Research Group
Department of Medicine
Faculty of Medical and Health Sciences
University of Auckland
85 Park Rd, Grafton, Auckland 1023</address>
      <phone> +64 (0) 9 3737999 x82568 </phone>
      <fax> +64 (0) 9 3737677</fax>
      <email>n.dalbeth@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>